Sandoz Strengthens Biosimilar Leadership with Acquisition Of Just-Evotec Biologics EU SAS; Secures Toulouse Site And Continuous Manufacturing Tech To Boost Biosimilar Scale

Sandoz has finalized its acquisition of Just-Evotec Biologics EU SAS from Evotec SE, securing the Toulouse biologics development and manufacturing facility along with an indefinite license to advanced continuous-manufacturing technology. This strategic move strengthens the company’s biosimilar capabilities by bringing cutting-edge process innovation directly in-house.

The acquisition supports Sandoz’s long-term biosimilars strategy by expanding its drug-substance development and manufacturing footprint. With global biosimilar opportunities expected to exceed USD 300 billion over the next decade, Sandoz is positioning itself to meet rising demand efficiently and competitively. The continuous-manufacturing technology acquired through this deal offers high throughput, automation, and significant scalability advantages.

Richard Saynor, CEO of Sandoz, said: “Biosimilars are the fastest-growing segment of our pipeline as the need of patients and healthcare systems for these critical medicines continues to grow rapidly. This acquisition is a pivotal step toward advancing our ambition to consolidate our position as the undisputed leader in biosimilars. It gives us greater control over our pipeline development and underscores our unwavering commitment to expanding access to high-quality, affordable biologics for millions of patients worldwide.”

Sandoz plans to tightly integrate the Toulouse site into its broader European network, complementing ongoing investment activity in Slovenia. While the Slovenian facility will continue focusing on large-scale fed-batch drug substance production, Toulouse will operate as a center of excellence for small-scale continuous manufacturing. This dual-site model creates operational synergies, enhances flexibility, and streamlines end-to-end biosimilar development.

The company noted that the transaction fits within planned capital expenditures and does not affect its 2025 financial outlook. All employees of JEB SAS have officially transitioned to Sandoz as of the transaction’s closing.